← Back to Influence Map
Entity DossierOrganization
ELI LILLY AND COMPANY
DC · US
Pharmaceutical company.
pharmaceuticals
Tracked direct giving
$0
LDA reported lobbying spend
$18,330,000
Connections
14
Lobbying Activity Detail
Disclosed lobbying expenditures from LDA filings where this entity is the client. Dollar amounts represent what was reported to the Senate Office of Public Records.
Top Lobbying Issues
HCRHealth Issues
$32.2MPHAPharmacy
$30.3MMMMMedicare/Medicaid
$30.1MTRDTrade
$29.3MCPTCopyright/Patent/Trademark
$28.0MTAXTaxation/Internal Revenue Code
$28.0MCSPConsumer Protection
$27.7MFORForeign Relations
$560KBUDBudget/Appropriations
$480KLobbying Firms Retained
In-house lobbyists (filed as its own registrant)$27.7M
BROWNSTEIN HYATT FARBER SCHRECK, LLP$1.1M
TIBER CREEK HEALTH STRATEGIES, INC.$960K
TODD STRATEGY GROUP$900K
FEROX STRATEGIES$840K
VENN STRATEGIES$730K
CHECKMATE GOVERNMENT RELATIONS$640K
MONUMENT ADVOCACY$560K
TARPLIN, DOWNS & YOUNG, LLC$480K
GRV STRATEGIES LLC$360K
THE SIMMONS & RUSSELL GROUP, LLC$360K
THORN RUN PARTNERS$320K
MARSHALL & POPP, LLC$300K
Lobbying data from Senate LDA filings and the LobbyView dataset (MIT/NSF, CC-BY-4.0). Dollar figures represent disclosed expenditures only and may not capture all influence activity. Issue codes follow the LDA general issue classification.
Connection Graph
0 nodes · 0 edgesHover for labels · Double-click to expand
Loading graph...
Person
Organization
PAC
Gov Body
Legislature
Think Tank
Industry
Outcome
Click a node to see details
Double-click to expand its connections
Relationships
| Type | Connected To | Details | Source |
|---|---|---|---|
| Lobbied on | Insulin Price Caps - State-Level Legislation | LDA filing: lobbied on Insulin Price Caps, period 1st Quarter (Jan 1 - Mar 31), reported amount $1,470,000 | Source |
| Retained | THE SIMMONS & RUSSELL GROUP, LLC | Hired THE SIMMONS & RUSSELL GROUP, LLC to lobby on Insulin Price Caps | Source |
| Retained | TIBER CREEK HEALTH STRATEGIES, INC. | Hired TIBER CREEK HEALTH STRATEGIES, INC. to lobby on Pharmaceuticals | Source |
| Retained | TARPLIN, DOWNS & YOUNG, LLC | Hired TARPLIN, DOWNS & YOUNG, LLC to lobby on Insulin Price Caps | Source |
| Commented on | Centers for Medicare & Medicaid Services | Public comment on CMS-2026-0496: Patient Protection and Affordable Care Act, Benefit and Payment Parameters for 2027 and Basic Health Program | Source |
| Retained | VENN STRATEGIES | Hired VENN STRATEGIES to lobby (1st Quarter (Jan 1 - Mar 31) 2023) | Source |
| Retained | BROWNSTEIN HYATT FARBER SCHRECK, LLP | Hired BROWNSTEIN HYATT FARBER SCHRECK, LLP to lobby (1st Quarter (Jan 1 - Mar 31) 2023) | Source |
| Retained | TODD STRATEGY GROUP | Hired TODD STRATEGY GROUP to lobby (1st Quarter (Jan 1 - Mar 31) 2023) | Source |
| Retained | MONUMENT ADVOCACY | Hired MONUMENT ADVOCACY to lobby (1st Quarter (Jan 1 - Mar 31) 2023) | Source |
| Retained | THORN RUN PARTNERS | Hired THORN RUN PARTNERS to lobby (1st Quarter (Jan 1 - Mar 31) 2023) | Source |
| Retained | FEROX STRATEGIES | Hired FEROX STRATEGIES to lobby (1st Quarter (Jan 1 - Mar 31) 2023) | Source |
| Retained | GRV STRATEGIES LLC | Hired GRV STRATEGIES LLC to lobby (1st Quarter (Jan 1 - Mar 31) 2025) | Source |
| Retained | MARSHALL & POPP, LLC | Hired MARSHALL & POPP, LLC to lobby (1st Quarter (Jan 1 - Mar 31) 2025) | Source |
| Retained | CHECKMATE GOVERNMENT RELATIONS | Hired CHECKMATE GOVERNMENT RELATIONS to lobby (1st Quarter (Jan 1 - Mar 31) 2025) | Source |